Testing effectiveness (Phase 2)Ended earlyNCT00850577
What this trial is testing
Ph II of a Novel Anti-angiogenic Agent in Combination With Chemotherapy for the Treatment of Non-Small Cell Lung Cancer
Who this might be right for
Non-small Cell Lung Cancer (NSCLC)
Bristol-Myers Squibb 255